Issue 6, 2008

Bioorganometallic fulvene-derived titanocene anti-cancer drugs

Abstract

6-Substituted fulvenes are interesting and easily accessible starting materials for the synthesis of novel substituted titanocenes via reductive dimerisation, carbolithiation or hydridolithiation reactions, which are followed by a transmetallation reaction with titanium tetrachloride in the latter two cases. Depending on the substitution pattern, these titanocenes prove to be bioorganometallic anti-cancer drugs, which have significant potential against advanced or metastatic renal-cell cancer. Patients bearing these stages of kidney cancer have a poor prognosis so far and therefore real progress in the area of metal-based anti-cancer drugs may come from this simple and effective synthetic approach. This tutorial review provides an insight into the synthesis of fulvene-derived titanocenes and their activity in preclinical experiments.

Graphical abstract: Bioorganometallic fulvene-derived titanocene anti-cancer drugs

Article information

Article type
Tutorial Review
Submitted
19 Feb 2008
First published
02 Apr 2008

Chem. Soc. Rev., 2008,37, 1174-1187

Bioorganometallic fulvene-derived titanocene anti-cancer drugs

K. Strohfeldt and M. Tacke, Chem. Soc. Rev., 2008, 37, 1174 DOI: 10.1039/B707310K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements